Overview
Noriko Minato practices practicing medicine in Sakai, Japan.
Her clinical expertise encompasses Metastatic Brain Tumor, Muscle Invasive Bladder Cancer, and Adrenal Cancer.
She is actively involved in clinical research, co-authoring 12 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Noriko Minato
Is Noriko Minato a top-rated expert for Metastatic Brain Tumor?
MediFind is an objective health platform that identifies experts based on real-world data. Noriko Minato is classified as an Experienced expert for Metastatic Brain Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Noriko Minato participate in research or clinical trials?
Yes. Noriko Minato has published 12 articles and abstracts on conditions like Metastatic Brain Tumor. You can view a list of Noriko Minato's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Adrenal CancerMs. Minato isExperienced. Learn about Adrenal Cancer.
- Metastatic Brain TumorMs. Minato isExperienced. Learn about Metastatic Brain Tumor.
- Muscle Invasive Bladder CancerMs. Minato isExperienced. Learn about Muscle Invasive Bladder Cancer.